Non-coding genomic elements and non-coding RNAs have been considered mostly non-functional for a long time. Today, we not only know that most of them are transcriptionally active, and play a critical role in several diseases, but we start to understand how they can be used in clinical practice. Circulating RNAs for example, have been demonstrated to be excellent candidates as minimally invasive biomarkers for the progression of diseases and monitoring the treatment. In recent years, several non-coding RNAs have been found misregulated and indicated as potential biomarkers in diabetes mellitus, Cushing syndrome, medullary thyroid carcinoma, pituitary adenoma, and pheochromocytoma. Furthermore, non-coding DNA regions start to be explored thoroughly due to the continuous decrease in costs of full genome deep sequencing. Understanding the role of non-coding DNA and RNA elements in endocrine diseases is an emerging field, which has the potential of discovering new insights into the pathophysiology of these diseases and answering essential questions that could provide new pathways for treatment.
This Research Topic aims to gather articles that are focusing on the latest advances in the field of non-coding genome in the pathophysiology and clinical evolution of endocrine diseases. We are interested in the following types of high-quality manuscripts: original research, systematic review and meta-analysis, narrative review, and mini-review, which are addressing the issue from fundamental research or clinical perspective.
We are interested in research studies investigating the following aspects of endocrine diseases:
• Non-coding RNAs as biomarkers
• Ultraconserved elements in endocrine diseases
• Pathophysiological advances in endocrinological diseases
• Non-coding RNAs in endocrine cancers
• Circulating biomarkers
• Non-coding genome as a therapeutic target in endocrinological diseases
• Non-coding genome alterations in endocrine diseases
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
COI: Dr. George A. Calin is the scientific founder of Ithax Pharmaceuticals
Non-coding genomic elements and non-coding RNAs have been considered mostly non-functional for a long time. Today, we not only know that most of them are transcriptionally active, and play a critical role in several diseases, but we start to understand how they can be used in clinical practice. Circulating RNAs for example, have been demonstrated to be excellent candidates as minimally invasive biomarkers for the progression of diseases and monitoring the treatment. In recent years, several non-coding RNAs have been found misregulated and indicated as potential biomarkers in diabetes mellitus, Cushing syndrome, medullary thyroid carcinoma, pituitary adenoma, and pheochromocytoma. Furthermore, non-coding DNA regions start to be explored thoroughly due to the continuous decrease in costs of full genome deep sequencing. Understanding the role of non-coding DNA and RNA elements in endocrine diseases is an emerging field, which has the potential of discovering new insights into the pathophysiology of these diseases and answering essential questions that could provide new pathways for treatment.
This Research Topic aims to gather articles that are focusing on the latest advances in the field of non-coding genome in the pathophysiology and clinical evolution of endocrine diseases. We are interested in the following types of high-quality manuscripts: original research, systematic review and meta-analysis, narrative review, and mini-review, which are addressing the issue from fundamental research or clinical perspective.
We are interested in research studies investigating the following aspects of endocrine diseases:
• Non-coding RNAs as biomarkers
• Ultraconserved elements in endocrine diseases
• Pathophysiological advances in endocrinological diseases
• Non-coding RNAs in endocrine cancers
• Circulating biomarkers
• Non-coding genome as a therapeutic target in endocrinological diseases
• Non-coding genome alterations in endocrine diseases
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
COI: Dr. George A. Calin is the scientific founder of Ithax Pharmaceuticals